ITOS vs. JANX, ETNB, ADPT, DYN, SPRY, EVO, TVTX, ANIP, MESO, and OCUL
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Janux Therapeutics (JANX), 89bio (ETNB), Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), ARS Pharmaceuticals (SPRY), Evotec (EVO), Travere Therapeutics (TVTX), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs. Its Competitors
iTeos Therapeutics (NASDAQ:ITOS) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 8.1% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
iTeos Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500.
iTeos Therapeutics currently has a consensus target price of $15.86, suggesting a potential upside of 57.31%. Janux Therapeutics has a consensus target price of $95.25, suggesting a potential upside of 278.43%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than iTeos Therapeutics.
In the previous week, iTeos Therapeutics had 14 more articles in the media than Janux Therapeutics. MarketBeat recorded 24 mentions for iTeos Therapeutics and 10 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.13 beat iTeos Therapeutics' score of 0.15 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Janux Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat iTeos Therapeutics' return on equity.
iTeos Therapeutics received 5 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 73.13% of users gave iTeos Therapeutics an outperform vote while only 70.97% of users gave Janux Therapeutics an outperform vote.
Summary
Janux Therapeutics beats iTeos Therapeutics on 11 of the 19 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ITOS Stock Free ITOS Stock Alerts